Subscribe
head-istock-489931178_stockdevil
stockdevil /iStockphoto.com
13 March 2017Americas

Actavis and Zydus settle with Supernus over seizure drug

Speciality pharmaceutical company Supernus has settled patent disputes over Trokendi XR (topiramate), a treatment for partial seizures, with US-based Zydus Pharmaceuticals and Actavis Laboratories.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Takeda v Zydus: FTC intervenes in sham lawsuit claims
11 June 2018   The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Americas
Supernus hits Zydus with repeat suit over migraine drug
20 September 2021   Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.
Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Takeda v Zydus: FTC intervenes in sham lawsuit claims
11 June 2018   The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Americas
Supernus hits Zydus with repeat suit over migraine drug
20 September 2021   Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.
Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.

More on this story

Americas
Takeda v Zydus: FTC intervenes in sham lawsuit claims
11 June 2018   The US Federal Trade Commission has filed an amicus brief urging a district court to reject Takeda’s claim that its patent infringement lawsuit brought under the Hatch-Waxman Act cannot be a sham.
Americas
Supernus hits Zydus with repeat suit over migraine drug
20 September 2021   Supernus Pharmaceuticals has once again accused Indian generic drugmaker Zydus Cadila and its US unit of allegedly infringing 10 patents with its copycat of Trokendi XR (topiramate), a drug for migraines and seizures.
Big Pharma
Zydus challenges ruling in Takeda antitrust dispute
16 June 2022   Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?